CytRx Corporation is a clinical-stage, biopharmaceutical company focused on discovering, developing and commercializing new therapeutics to treat patients with cancer. CytRx’s initial focus is on seeking regulatory approval for and commercialization of it’s lead drug candidate, aldoxorubicin, an improved version of the widely used chemotherapeutic agent doxorubicin. Aldoxorubicin is currently in late-stage clinical development for the treatment of relapsed soft tissue sarcoma, and is also being evaluated in several other cancer indications with significant unmet clinical need, including small-cell lung cancer. CytRx plans to expand its pipeline of oncology candidates using its Linker Activated Drug Release, or LADR, technology platform. The company’s LADR research efforts currently center on creating new molecules from the combination of ultra high potency cytotoxic payloads with novel, tunable linkers. The LADR technology employs a broad portfolio of novel linker molecules that selectively bind to circulating albumin and have the ability to be linked to a wide variety of anticancer payloads. Research efforts currently center on creating new molecules from the combination of ultra-high potency cytotoxic payloads with tunable linkers. The molecules currently being evaluated concentrate at the tumor site providing targeted delivery of the chemotherapeutic payloads. For more on CytRX, visit the companies website.